Stage III Rectal Cancer
24
0
0
17
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
4 terminated out of 24 trials
81.0%
-5.6% vs benchmark
13%
3 trials in Phase 3/4
18%
3 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (24)
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
The Role of Vitamin D in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated